Search
Zaleplon
go.drugbank.com/drugs/DB00962ApprovedIllicitZaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. … Zaleplon is a schedule IV drug in the United States.
Synonyms: 3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilideCategories: Heterocyclic Compounds, 1-Ring, GABA-A Receptor AgonistsAbatacept
go.drugbank.com/drugs/DB01281ApprovedInvestigational[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each … Although approved for the treatment of rheumatoid arthritis, Repligen has entered a slightly different formulation of CTLA4-Ig into clinical trials (RG2077).
Categories: Selective T Cell Costimulation ModulatorProducts: ORENCIA® 250 MG - POLVO LIOFILIZADO PARA SOLUCIÓN INYECTABLE INTRAVENOSA, ORENCIA 250 MG KON.PERFUZYONLUK COZ.ICIN TOZ ICEREN FLAKONNilotinib
go.drugbank.com/drugs/DB04868ApprovedInvestigationalNilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). … ), another tyrosine kinase inhibitor used as a first-line treatment for CML.
Categories: Heterocyclic Compounds, 1-Ring, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: TASIGNA® 150 MG CAPSULAS, TASIGNA 150 MG KAPSUL, 28 ADETAdalimumab
go.drugbank.com/drugs/DB00051ApprovedInvestigationalIt is produced by recombinant DNA technology using a mammalian cell expression system. … [A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA.[A39983] This drug is frequently known as _Humira_.
Products: AMGEVITA 40 MG ILO I E PEN, AMGEVİTA 20 MG/0.4 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETHydrotalcite
go.drugbank.com/drugs/DB13322ApprovedInvestigationalWithdrawnProducts: TALCID 500 MG CIGNEME TABLETI, 40 ADET, HIDRASIT 1000 MG ÇİĞNEME TABLET, 24 ADETDupilumab
go.drugbank.com/drugs/DB12159ApprovedInvestigational[L7186,L7192,L41439] Dupilumab is currently under investigations for potential therapeutic use in diseases driven by allergic reactions or type 2 inflammation, such as pediatric atopic dermatitis, and … [L7186] Dupilumab is commonly marketed as Dupixent, which is available as a formulation for subcutaneous injection. It was first approved by the FDA in 2017.
Categories: Interleukin-4 Receptor alpha Antagonist, Interleukin 4 Receptor alpha AntagonistsProducts: DUPİXENT 200 mg/ 1,14ml ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET, DUPİXENT 300 MG/2ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETN-[(2S,3S)-4-[2-[(5S)-3a,4,5,6,7,7a-Hexahydro-1,3-benzodioxol-5-yl]ethyl-[3-(1,3-dioxoisoindol-2-yl)propanoyl]amino]-3-hydroxy-1-phenylbutan-2-yl]-3,5-dimethoxy-4-phenylmethoxybenzamide
go.drugbank.com/drugs/DB03063ExperimentalSynonyms: N-[(2S,3S)-4-[2-[(5S)-3a,4,5,6,7,7a-Hexahydro-1,3-benzodioxol-5-yl]ethyl-[3-(1,3-dioxoisoindol-2-yl)propanoyl]amino]-3-hydroxy-1-phenylbutan-2-yl]-3,5-dimethoxy-4-phenylmethoxybenzamideNivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigationalNivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). … [A35203] It was developed by Bristol Myers Squibb.[L12129] Nivolumab was granted FDA approval on 22 December 2014.
Synonyms: ABP 206Mixtures: OPDUALAG® SOLUCION INYECTABLEFelbamate
go.drugbank.com/drugs/DB00949ApprovedAlternatively, it is used to treat partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites. … In particular, in the adult patient population, it can be employed to treat partial seizures (with and without generalization).
Synonyms: Carbamic acid 3-carbamoyloxy-2-phenyl-propyl ester, 2-phenyl-1,3-propanediol dicarbamateCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersTestosterone enanthate
go.drugbank.com/drugs/DB13944ApprovedInvestigationalAs recent as 1 October 2018, the US FDA approved Antares Pharma Inc.' … s Xyosted - a subcutaneous testosterone enanthate product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable autoinjector [L4659].
Mixtures: NOFERTYL® INYECTABLECategories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates